Total Payments
$785,755
2024 Payments
$37,909
Companies
15
Transactions
607
Medicare Patients
1,497
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$651,585 (82.9%)
Consulting$94,670 (12.0%)
Food & Beverage$19,288 (2.5%)
Travel$13,864 (1.8%)
Research$5,156 (0.7%)
Gifts$890.00 (0.1%)
Education$301.11 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $642,735 | 199 | 81.8% |
| Consulting Fee | $94,670 | 23 | 12.0% |
| Food and Beverage | $19,288 | 293 | 2.5% |
| Travel and Lodging | $13,864 | 62 | 1.8% |
| Honoraria | $8,850 | 5 | 1.1% |
| Unspecified | $5,156 | 17 | 0.7% |
| Gift | $890.00 | 1 | 0.1% |
| Education | $301.11 | 7 | 0.0% |
Payments by Type
General
$780,598
590 transactions
Research
$5,156
17 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $294,474 | 182 | $0 (2024) |
| Genentech USA, Inc. | $195,219 | 135 | $0 (2024) |
| GENZYME CORPORATION | $178,803 | 146 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $72,540 | 74 | $0 (2023) |
| Horizon Therapeutics plc | $13,321 | 14 | $0 (2023) |
| Celgene Corporation | $8,310 | 7 | $0 (2018) |
| Amgen Inc. | $7,668 | 9 | $0 (2024) |
| EMD Serono, Inc. | $6,670 | 7 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $5,617 | 4 | $0 (2017) |
| Genentech, Inc. | $2,464 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $37,909 | 33 | Genentech USA, Inc. ($14,955) |
| 2023 | $49,125 | 48 | Biogen, Inc. ($25,265) |
| 2022 | $90,494 | 51 | Biogen, Inc. ($44,524) |
| 2021 | $57,664 | 42 | Genentech USA, Inc. ($23,056) |
| 2020 | $64,479 | 52 | Biogen, Inc. ($43,594) |
| 2019 | $161,142 | 116 | GENZYME CORPORATION ($54,367) |
| 2018 | $162,862 | 130 | Biogen, Inc. ($44,482) |
| 2017 | $162,080 | 135 | Biogen, Inc. ($67,782) |
All Payment Transactions
607 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| 11/26/2024 | Genentech, Inc. | Ocrevus | Food and Beverage | In-kind items and services | $48.55 | General |
| 11/19/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,520.00 | General |
| Category: Immunology | ||||||
| 11/19/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $120.69 | General |
| 11/14/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| Category: Neurology | ||||||
| 11/14/2024 | Biogen, Inc. | VUMERITY (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Neurology | ||||||
| 11/07/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 10/15/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $79.19 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/10/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $48.88 | General |
| Category: Immunology | ||||||
| 09/13/2024 | Biogen, Inc. | VUMERITY (Drug) | Consulting Fee | Cash or cash equivalent | $685.00 | General |
| Category: Neurology | ||||||
| 08/09/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 07/31/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $117.93 | General |
| 06/28/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,700.00 | General |
| 06/28/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| 06/20/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $125.01 | General |
| 06/06/2024 | Biogen, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,795.00 | General |
| 06/06/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $64.80 | General |
| 05/23/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,520.00 | General |
| Category: Immunology | ||||||
| 05/23/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $274.70 | General |
| Category: Immunology | ||||||
| 05/23/2024 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Immunology | ||||||
| 05/15/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $23.65 | General |
| 05/06/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $44.63 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $79.45 | General |
| Category: Inflammation/Rare Disease | ||||||
| 04/18/2024 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Neurology | ||||||
| 04/15/2024 | TG Therapeutics, Inc. | BRIUMVI (Drug) | Food and Beverage | In-kind items and services | $54.79 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS03409) | GENZYME CORPORATION | $1,754 | 6 |
| An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | GENZYME CORPORATION | $1,302 | 6 |
| A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients With Relapsing-Remitting Multiple Sclerosis | GENZYME CORPORATION | $1,250 | 1 |
| A Long-Term Follow-Up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS3409),An Extension Protocol for Multiple Scerlosis Patients Who Participated in Gen | GENZYME CORPORATION | $472.94 | 1 |
| A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) | GENZYME CORPORATION | $190.26 | 2 |
| A long-term follow up study for multiple sclerosis patients who have completed the alemtuzumab extension study | GENZYME CORPORATION | $187.06 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 363 | 519 | $153,591 | $35,990 |
| 2022 | 15 | 410 | 28,219 | $2.1M | $524,843 |
| 2021 | 13 | 351 | 36,577 | $2.6M | $692,112 |
| 2020 | 13 | 373 | 36,966 | $2.0M | $659,647 |
Total Patients
1,497
Total Services
102,281
Medicare Billing
$1.9M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 85 | 109 | $40,684 | $8,635 | 21.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 50 | 50 | $26,266 | $6,623 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 71 | 86 | $22,764 | $4,711 | 20.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 34 | $17,996 | $4,411 | 24.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 52 | $11,608 | $3,230 | 27.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 24 | 68 | $13,099 | $3,121 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 17 | 17 | $11,023 | $2,713 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 11 | $3,584 | $1,028 | 28.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 16 | 17 | $2,803 | $743.92 | 26.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 13 | 57 | $3,440 | $710.39 | 20.7% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 11 | 18 | $324.00 | $64.16 | 19.8% |
| J2323 | Injection, natalizumab, 1 mg | Office | 2022 | 12 | 27,600 | $1.9M | $484,496 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 102 | 125 | $45,870 | $9,689 | 21.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 41 | 46 | $24,248 | $5,249 | 21.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 16 | 91 | $18,814 | $4,788 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 29 | 30 | $17,220 | $4,591 | 26.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 46 | $13,558 | $3,706 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 57 | 65 | $16,863 | $3,426 | 20.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 30 | 30 | $11,690 | $3,187 | 27.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 15 | 23 | $9,570 | $1,937 | 20.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 26 | $5,352 | $1,398 | 26.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 11 | 58 | $5,111 | $1,311 | 25.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 11 | 11 | $3,017 | $496.56 | 16.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 11 | 12 | $1,336 | $365.62 | 27.4% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2022 | 12 | 22 | $386.00 | $102.86 | 26.6% |
About Dr. Thomas Scott, MD
Dr. Thomas Scott, MD is a Neurology healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093717092.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Scott, MD has received a total of $785,755 in payments from pharmaceutical and medical device companies, with $37,909 received in 2024. These payments were reported across 607 transactions from 15 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($642,735).
As a Medicare-enrolled provider, Scott has provided services to 1,497 Medicare beneficiaries, totaling 102,281 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Pittsburgh, PA
- Active Since 08/10/2005
- Last Updated 09/30/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1093717092
Products in Payments
- OCREVUS (Biological) $131,001
- AUBAGIO (Drug) $115,921
- VUMERITY (Drug) $80,461
- TYSABRI (Biological) $72,292
- TECFIDERA (Drug) $60,263
- LEMTRADA (Drug) $46,659
- GILENYA (Drug) $40,052
- Non-Covered Product (Drug) $36,866
- Ocrevus (Biological) $24,453
- ZINBRYTA (Biological) $18,384
- UPLIZNA (Drug) $13,321
- Ozanimod (Drug) $7,872
- Mavenclad (Biological) $6,394
- COPAXONE (Drug) $5,617
- Tysabri (Biological) $4,385
- KESIMPTA (Drug) $2,206
- PLEGRIDY (Biological) $1,695
- Enspryng (Biological) $1,673
- LEMTRADA (Biological) $1,278
- BRIUMVI (Drug) $483.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Pittsburgh
Dr. Raul Nogueira, Md, MD
Neurology — Payments: $1.1M
Neurology $1.1M
Anoopum Gupta, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $726,876
Neurology $726,876
James Valeriano, Md, MD
Neurology — Payments: $469,230
Neurology $469,230
Andrea Synowiec, Do, DO
Neurology — Payments: $437,510
Neurology $437,510
Amber Van Laar
Neurology — Payments: $413,359
Neurology $413,359
Dr. David Lobas, M.d, M.D
Neurology — Payments: $336,753
Neurology $336,753